Financhill
Buy
53

AKBA Quote, Financials, Valuation and Earnings

Last price:
$2.56
Seasonality move :
-4.02%
Day range:
$2.18 - $2.40
52-week range:
$0.80 - $2.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.16x
P/B ratio:
--
Volume:
4.6M
Avg. volume:
2.9M
1-year change:
41.18%
Market cap:
$567M
Revenue:
$160.2M
EPS (TTM):
-$0.33

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AKBA
Akebia Therapeutics
$37.4M -$0.08 36.1% -55.56% $7.83
ALDX
Aldeyra Therapeutics
-- -$0.22 -- -68.57% $10.00
CLRB
Cellectar Biosciences
-- -$0.35 -- -33.33% $5.67
LFWD
Lifeward
$7.8M -$0.33 21.74% -54.8% $9.00
MCRB
Seres Therapeutics
-- -$0.20 -100% -55.56% $3.82
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AKBA
Akebia Therapeutics
$2.40 $7.83 $567M -- $0.00 0% 3.16x
ALDX
Aldeyra Therapeutics
$6.31 $10.00 $376.8M -- $0.00 0% --
CLRB
Cellectar Biosciences
$0.34 $5.67 $13.9M -- $0.00 0% 730.55x
LFWD
Lifeward
$1.59 $9.00 $16.9M -- $0.00 0% 0.54x
MCRB
Seres Therapeutics
$0.74 $3.82 $128.7M -- $0.00 0% 0.93x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AKBA
Akebia Therapeutics
-368.79% 2.794 9.06% 1.07x
ALDX
Aldeyra Therapeutics
-- -1.486 -- --
CLRB
Cellectar Biosciences
-- 2.365 -- --
LFWD
Lifeward
-- -0.377 -- 1.25x
MCRB
Seres Therapeutics
-- -1.064 -- --
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AKBA
Akebia Therapeutics
$26.1M -$14.3M -9553.8% -- -34.25% -$4.5M
ALDX
Aldeyra Therapeutics
-- -$16.6M -- -- -- -$12M
CLRB
Cellectar Biosciences
-- -$13.3M -- -- -- -$9.2M
LFWD
Lifeward
$1.8M -$5.4M -81.96% -81.96% -72.02% -$4M
MCRB
Seres Therapeutics
-- -$28.8M -- -- -- -$39M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M

Akebia Therapeutics vs. Competitors

  • Which has Higher Returns AKBA or ALDX?

    Aldeyra Therapeutics has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Aldeyra Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    56.2% -$0.10 -$10.5M
    ALDX
    Aldeyra Therapeutics
    -- -$0.27 --
  • What do Analysts Say About AKBA or ALDX?

    Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Aldeyra Therapeutics has an analysts' consensus of $10.00 which suggests that it could grow by 58.48%. Given that Akebia Therapeutics has higher upside potential than Aldeyra Therapeutics, analysts believe Akebia Therapeutics is more attractive than Aldeyra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    1 0 0
    ALDX
    Aldeyra Therapeutics
    6 0 0
  • Is AKBA or ALDX More Risky?

    Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Aldeyra Therapeutics has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.262%.

  • Which is a Better Dividend Stock AKBA or ALDX?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Aldeyra Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or ALDX?

    Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Aldeyra Therapeutics quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Aldeyra Therapeutics's net income of -$15.8M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Aldeyra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus -- for Aldeyra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    3.16x -- $46.5M -$22.8M
    ALDX
    Aldeyra Therapeutics
    -- -- -- -$15.8M
  • Which has Higher Returns AKBA or CLRB?

    Cellectar Biosciences has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Cellectar Biosciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    56.2% -$0.10 -$10.5M
    CLRB
    Cellectar Biosciences
    -- -$0.40 --
  • What do Analysts Say About AKBA or CLRB?

    Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Cellectar Biosciences has an analysts' consensus of $5.67 which suggests that it could grow by 1582.5%. Given that Cellectar Biosciences has higher upside potential than Akebia Therapeutics, analysts believe Cellectar Biosciences is more attractive than Akebia Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    1 0 0
    CLRB
    Cellectar Biosciences
    1 1 0
  • Is AKBA or CLRB More Risky?

    Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.963, suggesting its less volatile than the S&P 500 by 3.676%.

  • Which is a Better Dividend Stock AKBA or CLRB?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or CLRB?

    Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Cellectar Biosciences quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Cellectar Biosciences's net income of -$14.7M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 730.55x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    3.16x -- $46.5M -$22.8M
    CLRB
    Cellectar Biosciences
    730.55x -- -- -$14.7M
  • Which has Higher Returns AKBA or LFWD?

    Lifeward has a net margin of -49.04% compared to Akebia Therapeutics's net margin of -202.49%. Akebia Therapeutics's return on equity of -- beat Lifeward's return on equity of -81.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    56.2% -$0.10 -$10.5M
    LFWD
    Lifeward
    24.44% -$1.73 $18.8M
  • What do Analysts Say About AKBA or LFWD?

    Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Lifeward has an analysts' consensus of $9.00 which suggests that it could grow by 466.04%. Given that Lifeward has higher upside potential than Akebia Therapeutics, analysts believe Lifeward is more attractive than Akebia Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    1 0 0
    LFWD
    Lifeward
    1 0 0
  • Is AKBA or LFWD More Risky?

    Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Lifeward has a beta of 1.732, suggesting its more volatile than the S&P 500 by 73.212%.

  • Which is a Better Dividend Stock AKBA or LFWD?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or LFWD?

    Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Lifeward quarterly revenues of $7.5M. Akebia Therapeutics's net income of -$22.8M is lower than Lifeward's net income of -$15.3M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 0.54x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    3.16x -- $46.5M -$22.8M
    LFWD
    Lifeward
    0.54x -- $7.5M -$15.3M
  • Which has Higher Returns AKBA or MCRB?

    Seres Therapeutics has a net margin of -49.04% compared to Akebia Therapeutics's net margin of --. Akebia Therapeutics's return on equity of -- beat Seres Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    56.2% -$0.10 -$10.5M
    MCRB
    Seres Therapeutics
    -- -$0.11 --
  • What do Analysts Say About AKBA or MCRB?

    Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand Seres Therapeutics has an analysts' consensus of $3.82 which suggests that it could grow by 418.23%. Given that Seres Therapeutics has higher upside potential than Akebia Therapeutics, analysts believe Seres Therapeutics is more attractive than Akebia Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    1 0 0
    MCRB
    Seres Therapeutics
    4 1 0
  • Is AKBA or MCRB More Risky?

    Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison Seres Therapeutics has a beta of 2.186, suggesting its more volatile than the S&P 500 by 118.578%.

  • Which is a Better Dividend Stock AKBA or MCRB?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seres Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Seres Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or MCRB?

    Akebia Therapeutics quarterly revenues are $46.5M, which are larger than Seres Therapeutics quarterly revenues of --. Akebia Therapeutics's net income of -$22.8M is lower than Seres Therapeutics's net income of -$15.6M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Seres Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 0.93x for Seres Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    3.16x -- $46.5M -$22.8M
    MCRB
    Seres Therapeutics
    0.93x -- -- -$15.6M
  • Which has Higher Returns AKBA or NBY?

    NovaBay Pharmaceuticals has a net margin of -49.04% compared to Akebia Therapeutics's net margin of -49.65%. Akebia Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    56.2% -$0.10 -$10.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About AKBA or NBY?

    Akebia Therapeutics has a consensus price target of $7.83, signalling upside risk potential of 226.39%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Akebia Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Akebia Therapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is AKBA or NBY More Risky?

    Akebia Therapeutics has a beta of 0.946, which suggesting that the stock is 5.43% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock AKBA or NBY?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or NBY?

    Akebia Therapeutics quarterly revenues are $46.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Akebia Therapeutics's net income of -$22.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 3.16x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    3.16x -- $46.5M -$22.8M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock